GenesisCare administers novel diagnostic agent Pylarify to first US patient

The phase 2 ProstACT TARGET study is exploring TLX591 (177Lu-DOTA-rosopatamab) in combination with external beam radiation therapy.

For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.

The phase 1/2 COBRA trial is exploring the novel PSMA-PET imaging agent 64Cu-SAR-bisPSMA in patients with biochemical recurrence.

The oncology provider will enable patient access to the PSMA-PET imaging agent piflufolastat F 18, which the FDA approved in May 2021 for identifying suspected metastasis or recurrence of prostate cancer.

Amid a recent FDA approval and impressive phase 3 data shared during ASCO, there has been a flurry of activity in the PSMA space.